 The Phosphate Company Ltd Q2FY26 loss at Rs. 2.48 crore
The Phosphate Company Ltd Q2FY26 loss at Rs. 2.48 crore Emami Paper Mills Ltd Q2 FY2026 profit at Rs. 6.58 crores
Emami Paper Mills Ltd Q2 FY2026 profit at Rs. 6.58 crores Maruti Suzuki India Ltd Q2 FY2026 consolidated PAT slips QoQ to Rs. 3349 crores
Maruti Suzuki India Ltd Q2 FY2026 consolidated PAT slips QoQ to Rs. 3349 crores RattanIndia Power Ltd consolidated Q2FY26 loss at Rs. 31.55 crores
RattanIndia Power Ltd consolidated Q2FY26 loss at Rs. 31.55 crores Dr Lal Path Labs Ltd reports Rs. 150.6 crores consolidated profit in Q2 FY26
Dr Lal Path Labs Ltd reports Rs. 150.6 crores consolidated profit in Q2 FY26 
              Mumbai, October 19, 2006: Lupin Ltd today announced that Mr.Edward R.Roberts has joined the company's board as an Independent Director.
Mr.Roberts, a British Citizen, residing in Germany, is a 1959 pharmacy graduate from Leicester University. He has wide experience in the international pharma industry. He is the Chairman of the Board of "Biopartners", (a Swiss biotech company) and "Merz Pharma", (a well known German pharma company). He is also a member of the Board of "Icon", a listed US Contact Research Organisation. He is also an advisor to "Avista", a US private equity company.
Till the year 1998, he was the Head of Pharmaceuticals at 'E Merck', a leading German pharma company, prior to which he spent 27 years at 'Eli Lilly' was as President of 'Elanco', the agricultural division of 'Eli Lilly'.
Welcoming Mr.Robers on the Board, Dr.Desh Bandhu Gupta, Chairman, said "I am delighted that an internationally renowned person like Mr.Roberts has accepted our invitation to join the Board. His enormous experience and deep knowledge of the International pharma business will prove to be a valuable asset for Lupin."